| Code | CSB-RA009438MB3HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is a research-grade biosimilar of the GIPR antibody disclosed in CN 112521501 A, targeting GIPR (gastric inhibitory polypeptide receptor; also known as the glucose-dependent insulinotropic polypeptide receptor), a class B1 G protein-coupled receptor (GPCR). GIPR is the cognate receptor for the incretin hormone GIP and signals primarily through G proteins to activate adenylyl cyclase and cAMP pathways, thereby regulating nutrient-stimulated endocrine and metabolic responses such as insulin secretion and broader glucose–lipid homeostasis.
CN 112521501 A describes anti-GIPR antibodies and fusion formats combining a GIPR antibody with GLP-1 to modulate metabolic pathways relevant to obesity, type 2 diabetes, and related metabolic diseases.This biosimilar provides the antibody component alone, enabling researchers to investigate GIPR biology, including ligand–receptor pathway modulation, receptor engagement and trafficking, and downstream signaling readouts (e.g., cAMP-linked responses), independent of any GLP-1 fusion/conjugate effects. It supports assay development and mechanistic studies that probe how GIPR-targeting antibodies may reshape incretin-network signaling and metabolic phenotypes in controlled experimental systems.
There are currently no reviews for this product.